

1 **A triple bottom line approach to antimicrobial stewardship: the effects of**
2 **simplifying treatment**

3 Michelle Balm^{1,2}, Olivia Bupha-Intr¹, Tanya Sinha², Matthew Kelly¹, Lucy Stewart³, Ruth Stephen⁴, Tim
4 Blackmore^{1,2}, Max Bloomfield*^{1,2}

5 1. Department of Infection Services, Te Whatu Ora/Health New Zealand, Capital, Coast and
6 Hutt Valley, Wellington, NZ

7 2. Department of Microbiology, Awanui Laboratories Wellington, Wellington, NZ

8 3. Department of Pharmacy, Te Whatu Ora/Health New Zealand, Capital, Coast and Hutt
9 Valley, Wellington, NZ

10 4. Department of Surgical Services, Te Whatu Ora/Health New Zealand, Capital, Coast and Hutt
11 Valley, Wellington, NZ

12

13 ***Corresponding author:**

14 M Bloomfield; maxim.bloomfield@ccdhb.org.nz;

15 Wellington Regional Hospital

16 Riddiford Street

17 Newtown

18 Wellington 6019

19 New Zealand

20

21

22 **Abstract:**

23 Aim: Our antimicrobial guidelines (AGs) were changed in 2021 to recommend once-daily ceftriaxone
24 in place of three-times-daily cefuroxime as preferred cephalosporin. This analysis sought to assess
25 the effects of this on incidence of *Clostridioides difficile* infection (CDI), third-generation
26 cephalosporin resistant Enterobacterales (3GCR-E), and resource utilisation.

27 Method: Before and after analysis of 30-day CDI and 3GCR-E incidence following receipt of
28 cefuroxime/ceftriaxone pre- and post-AG change. Total nursing time and waste production relating
29 to cefuroxime/ceftriaxone delivery were calculated pre- and post-change.

30 Results: CDI incidence was 0.6% pre- and 1.0% post-change (adjusted odds ratio [aOR] 1.44, p=0.07)
31 and 3GCR-E incidence 3.5% and 3.1% (aOR 0.90, p=0.33). Mean per-quarter estimated nursing
32 administration time decreased from 2065 to 1163 hours (902 nurse-hour reduction) and antibiotic-
33 related waste generation from 1131kg to 748kg (383kg reduction). Overall days of therapy per-
34 quarter of cefuroxime/ceftriaxone were unchanged between periods.

35 Conclusion: This simplification of our AG from a three-times-daily to a once-daily antibiotic resulted
36 in considerable savings for our hospital (roughly 1.7 full-time equivalent nurses and over a tonne of
37 waste yearly), with no significant increases in CDI or 3GCR-E. The impact of dosing schedules on non-
38 antibiotic-spectrum factors, such nursing time and resource usage, is worthy of consideration when
39 designing AGs.

40

41

42 **Introduction**

43 A core tool in hospital antimicrobial stewardship (AMS) is the development of syndrome-specific
44 antimicrobial guidelines (AGs).¹ Guideline-adherent empirical therapy is associated with reduced
45 treatment failure, length of stay (LOS) and mortality.² Guideline development typically focuses on
46 antimicrobial spectrum, route of administration, dose and duration. We believe that AMS should
47 also promote responsible and sustainable use of limited resources including nursing time, patient
48 comfort and convenience, and consumption of single-use plastic destined for landfill. This has
49 parallels to the business concept of the ‘triple bottom line’, whereby success is measured not solely
50 based on profit, but also in relation to the impact on people and the planet.

51 Using these principles, the AMS Committee at our institution changed the AGs in quarter 4 (Q4)
52 2021 to replace cefuroxime 1.5 g intravenous (IV) 8-hourly with ceftriaxone 2 g IV once daily as the
53 preferred cephalosporin for empiric treatment of a number of indications. Ceftriaxone was already
54 the recommended beta-lactam for moderate-severe community acquired pneumonia. This change
55 generated considerable debate within the committee, particularly regarding the potential to drive
56 antimicrobial resistance and *Clostridioides difficile* infection (CDI). Balancing this potential risk were
57 the likely benefits to the hospital system in terms of simplicity (to promote adherence), nursing time
58 saved and reduction in consumables. Convenience for patients was a major consideration with less
59 disruption to rest and fewer missed or late doses. The aim of this report is to describe the positive
60 and negative impacts of the change two years after implementation.

61

62 **Methods**

63 *Setting*

64 Wellington Regional Hospital (WRH) is a 484-bed acute care tertiary hospital which covers all
65 specialties except plastic surgery and rheumatology, and is aligned with Kenepuru Hospital (KPH), a
66 131-bed community hospital. These hospitals service a population of around 500,000 people.

67 In Q4 2021, in addition to the AG changes described above, piperacillin-tazobactam was changed to
68 cefepime for febrile neutropenia and severe hospital-acquired infection, and piperacillin-tazobactam
69 changed to amoxicillin-clavulanate for mild-moderate hospital-acquired infection. There was
70 widespread internal communication regarding these changes, and our AGs were updated on our
71 hospital intranet and mobile app.³

72 *Data extraction and creation of cohorts*

73 Medication dispensing at WRH/KPH uses BD Pyxis™, which permits data extraction for all individual
74 dispensing events. The exception to this is the Emergency Department (ED), for which dispensing
75 records were unavailable. The Pyxis data were used to create two cohorts for analysis: 1) patients
76 aged >16 years who received at least 2 consecutive days of either IV cefuroxime or IV ceftriaxone; 2)
77 patients aged >16 years who received at least 2 consecutive days of any other antibiotic via any
78 route. Patients were excluded from this group if they had received cefuroxime, ceftriaxone,
79 piperacillin-tazobactam, cefepime or amoxicillin-clavulanate within 30 days before or after the start
80 of their course. The intention of the second cohort was to provide a comparator group with
81 antibiotic use that was relatively unaffected by AG changes. Patient demographics and admission
82 information were extracted from the hospital data warehouse, and microbiology data were
83 extracted from the Awanui Laboratories Wellington laboratory information system, which provides
84 both hospital and community microbiology services for the entire region.

85 *Definitions*

86 The pre-change period was defined as 2019 Q1 to 2021 Q3, and the post-change period as 2022 Q1
87 to 2023 Q3. Q4 2021 was excluded because the new AGs were only partially embedded at this time.

88 For each patient incident CDI was defined as either a positive direct fecal toxin enzyme
89 immunoassay result or a positive toxigenic culture result within 2-30 days of the start of the
90 antibiotic course. Incident ESBL/third-generation cephalosporin-resistant Enterobacterales
91 (ESBL/3GCR-E) were defined as isolation of one of these organisms from any sample type within the
92 same time window. An overnight dose of an antibiotic was defined as a dispensing event between
93 10pm and 6am.

94 *Estimates of administration time and waste*

95 The time taken to administer a dose of IV antibiotics was estimated at 22 minutes.⁴ Weight
96 estimates were obtained by collecting all the waste (antibiotic vials, giving sets, tubing, syringes,
97 gloves, etc.) associated with delivery of each antibiotic over a 24-hour period and then dividing by
98 the number of doses to generate an average weight per dose. Given the scarcity of patients on
99 cefuroxime in the hospital, these weights were estimated from IV amoxicillin-clavulanate, which has
100 the same dose frequency and almost exactly the same use of vials and consumables. This gave a
101 weight of 84.5 g and 239.1 g for a 2 g dose of ceftriaxone via push and infusion, respectively, and
102 103.3 g and 195.6 g for cefuroxime. The infusion weight was used to estimate the overall waste
103 generation because this is the predominant mode of delivery in our institution.

104

105 *Analysis*

106 Outcomes of interest were: 1) the 30-day incidence of CDI and ESBL/3GCR-E in each cohort; 2)
107 estimated total nursing time spent administering IV antibiotics, estimated total IV-associated waste
108 generation, and total overnight doses administered in the cephalosporin cohort. These outcomes
109 were compared across the time periods, with the Chi-squared test used to compare categorical
110 variables, and the Mann-Whitney-U test for continuous variables. A multivariate logistic regression
111 model was created to determine which covariates in the cephalosporin cohort were independently

112 associated with increased odds of CDI and ESBL/3GCR-E. Analysis was performed in Stata 17 (College
113 Station, Texas). This analysis was part of the routine ongoing monitoring activities undertaken at our
114 hospital by the AMS committee, which is an ongoing Continuous Quality Improvement project to
115 inform future guidelines. It was therefore out of scope for Health and Disability Ethics Committee
116 review, as this analysis is classified as an 'audit or related activity'. Hospital Clinical Audit Committee
117 approval was gained.

118

119 **Results**

120 The characteristics of the cephalosporin cohort are shown in Table 1. In the pre-change period,
121 85.7% of the cohort received cefuroxime, whereas in the post-change period 94.2% received
122 ceftriaxone, consistent with the change in AGs. The pre- and post-change groups were otherwise
123 broadly similar, other than a decrease in general surgical patients and an increase in general medical
124 patients in the post-change period. Mean days of therapy (DOT) with cefuroxime/ceftriaxone within
125 30 days of the initial dose were similar across time periods (4.1 vs 4.0, $p=0.01$). CDI incidence was
126 0.6% in the pre-change, versus 1.0% in the post-change period ($p=0.02$). Isolation of ESBL/3GCR-E
127 within 30-days was 3.5% pre-change versus 3.1% ($p=0.31$) post-change. Characteristics of the
128 comparator group are shown in Table 2. The major difference compared to the cephalosporin cohort
129 was that there were fewer general surgical patients (6.6% and 5.1% of the cohort pre- and post-
130 change) and more subspecialty surgical patients (39.8% and 46.5%). The incidence of CDI was lower
131 than the cephalosporin cohort and did not change between time periods (0.2% and 0.2%, $p=0.68$)
132 and incidence of ESBL/3GCR-E was not significantly different between periods (1.4% versus 1.7%,
133 $p=0.13$). Figure 1. shows CDI incidence over time in the two cohorts. The incidence increased prior to
134 the AG change in the cephalosporin cohort, appeared to peak shortly after the change, and
135 decreased after this, whereas the incidence appeared stable across both time periods in the
136 comparator group.

137 Table 3. shows the multivariate analysis results for CDI. Several covariates were associated with
138 increased odds of CDI in the cephalosporin cohort, with the strongest being a prior diagnosis of CDI
139 within the last year (aOR 11.3, 95%-CI 5.25-24.33, $p < 0.01$), and cefuroxime/ceftriaxone DOT within
140 30 days of index dose (aOR 1.07 for each additional DOT, 95%-CI 1.02-1.13, $p = 0.01$). The odds of CDI
141 in the post-change period was no longer statistically significantly higher than the pre-change period
142 (aOR 1.44, 95%-CI 0.97-2.12, $p = 0.07$). The results of the multivariate analysis for ESBL/3GCR-E
143 showed an aOR of 0.91 (95%-CI 0.74-1.11, $p = 0.34$) for incident ESBL/3GCR-E in the post-change
144 period (Supplementary materials).

145 Table 4. shows the hospital-wide effects of the change in cephalosporin AGs between time periods.
146 The hospital was busier in the post-change period (additional 2487 occupied bed days per quarter),
147 but despite this, total cefuroxime/ceftriaxone DOT was very similar (2595 DOT versus 2599 DOT per
148 quarter). As expected, there was a marked decrease in mean cefuroxime DOT per quarter (2067
149 versus 105) and increase for ceftriaxone (528 versus 2494). There was a large decrease in mean
150 combined cefuroxime/ceftriaxone dosing events per quarter (5633 to 3172, decrease of 2461),
151 which translated to large reductions in estimated nursing time consumption (2065 hours per quarter
152 versus 1163, reduction of 902) and estimated waste generated for infusion delivery (1131kg to
153 748kg, reduction of 383kg). The mean number of overnight dosing events also decreased
154 substantially (1777 versus 588, decrease of 1189 per quarter).

155

156 Discussion

157 This study demonstrates widespread hospital acceptance of pragmatic guidelines which take into
158 consideration nursing workloads and patient convenience, with no statistically significant increase in
159 CDI or resistant organisms. We argue that these principles should be significant considerations for
160 the development of AGs, and that AMS should consider this 'triple bottom line' framework, rather
161 than focusing solely on the implications of antibiotic spectrum. Our programme emphasizes the

162 importance of ongoing monitoring of resistant organisms and CDI, to ensure that we do not cause
163 harm to the wider patient group in the name of nursing and individual patient convenience.

164 NZ has a health workforce crisis, and it is especially important that nursing time is used optimally
165 with improvements in workflow implemented where possible.⁵ A major benefit with the guideline
166 change was the reduction in nursing time spent preparing and delivering IV antibiotics, primarily due
167 to recommending a once-daily antibiotic. A mean estimated reduction of 902 nursing hours per
168 quarter was realised, which equates to almost 10 hours per day, or roughly 1.7 full-time equivalent.
169 In a period when there is a shortage of nurses, the ability to reallocate scarce nursing resource to
170 other care priorities is a considerable advantage. Furthermore, overstretched nurses are known to
171 be less compliant with hand hygiene and other infection control principles, so a reduction in
172 workload may be beneficial in this regard, which is in line with the goals of AMS.⁶

173 Both ceftriaxone 2 g and cefuroxime 1.5 g can be administered as either a push (3-5 minutes for
174 cefuroxime, 4-8 minutes for ceftriaxone) or via a 30-minute infusion.⁷ While push administration is
175 associated with less waste and overall time of delivery, observation during this study showed that
176 infusion remains standard practise in our hospital. In several studies, an IV push antibiotic was
177 associated with reduced time spent delivering doses compared to infusions, faster time to first dose
178 and reduced consumables and costs per dose event.⁸⁻¹⁰ Antibiotic infusion may also result in
179 wastage of up to 24% of the dose if the residual volume is not flushed, an issue not present for bolus
180 dosing.¹⁰ A program to encourage IV push of appropriate antibiotics may be a useful next step at our
181 institution, although the convenience of being able to perform other tasks once an infusion has been
182 hung is a common advantage cited by our nurses, so the reported time savings of push
183 administration may be less relevant, although would still result in savings in waste.

184 Our findings suggest that a significant reduction in waste can be achieved with once-daily antibiotics
185 such as ceftriaxone. We estimated that up to 383kg per quarter of consumable waste, or over a
186 tonne of waste per year, was saved by the guideline changes (assuming infusion delivery; the

187 quarterly estimate would be 297kg if all delivery was via push). Hospital waste contributes almost
188 5% of global greenhouse gas emissions and uses substantial plastic consumables.^{11,12} In NZ, most of
189 the consumables are imported, adding to the emission footprint. Minimising single-use consumables
190 (IV tubing, syringes, flush vials, plastic fluid bags) should be a priority for hospitals given the threats
191 to human health from environmental contamination and climate change.^{11,12} It should be noted that
192 the time savings and waste generated are based on per-dose estimates and the final numbers
193 should not be considered exact, however they are likely to be a good indication of the magnitude of
194 potential savings.

195 Use of a once-a-day antibiotic improves patient comfort and convenience, and should eliminate the
196 need to give overnight doses, other than the first dose in patients presenting overnight. There was a
197 reduction of 1189 doses given overnight compared to the pre-change period. However, 22.6% of
198 doses were still given in the overnight period. This suggests a failure to chart antimicrobials at more
199 nurse- and patient-friendly times by doctors, who may not think of the negative impact on patient
200 sleep and workload for nurses overnight – a time where staffing levels are lower. Interventions
201 aimed at changing workflows including time of medication administration have been shown to be
202 successful at improving sleep disruption for patients.^{13,14} This is an area to target for prescriber
203 education in our institution. A further advantage of once daily dosing is that it frees up patient time
204 for other important aspects of their care, such as allied health, radiology, or other therapies.

205 Critics of our approach may emphasise the potential harms of ceftriaxone when compared to
206 cefuroxime due to its broader spectrum. Although there are theoretical concerns regarding the
207 emergence of antimicrobial resistance and CDI with use of broad-spectrum antibiotics, studies are
208 heterogenous and do not provide simple answers. Antibiotics clearly have a profound effect on the
209 microbiome, and this can be persistent but the effect is complex.¹⁵ Cephalosporins are associated
210 with increased carriage of AmpC and ESBL-producing organisms.¹⁶ Ceftriaxone and cefuroxime both
211 promote increases in *bla*_{CTX-M} abundance, with one study demonstrating a 22% per day increase in

212 CTX-M genes in patients exposed to cefuroxime and 10% increase for patients on ceftriaxone.¹⁷
213 Short course antibiotics impact less on AMR genes in gut microbiome, and some studies have shown
214 that the spectrum of antibiotics has less impact than duration of exposure, thus the impact on the
215 microbiome depends on a range of factors including duration, route of administration as well as
216 antibiotic spectrum.^{15,18,19} Our data to date did not show an increase in ESBL-producing organisms
217 relating to the change in cephalosporin AGs.

218 Data on antibiotic-specific risk for CDI is also challenging due to heterogenous methods and study
219 design. Miller recently showed that cefuroxime has a similar odds ratio for CDI to third generation
220 cephalosporins, however, their study used cefpodoxime rather than ceftriaxone.²⁰ The EUCLID study
221 showed CDI risk was based on complex factors, not just antibiotic selection, and were unable to
222 show a clear association with overall cephalosporin prescribing.²¹ An older systematic review and
223 meta-analysis showed an OR of 3.2 for ceftriaxone compared to 2.23 for cefuroxime for CDI.²² Our
224 data showed a non-statistically significant increase in 30-day CDI incidence in the post-change
225 period. However, the incidence appeared to have been gradually increasing over time prior to the
226 change, with a peak shortly after the change, and subsequent return towards baseline levels.
227 Ongoing surveillance will provide more robust data regarding the effects of guideline changes but so
228 far there are no convincing clinical data that establishes ceftriaxone to be a higher risk antibiotic
229 than cefuroxime for the risk of CDI or antimicrobial resistance.

230 The overall impact of initial empirical antimicrobials used in a hospital setting on the development of
231 resistant gram negatives and CDI is likely to be less significant than the ongoing antimicrobial use in
232 terms of spectrum and duration, and that of community prescribing, which in NZ accounts for
233 around 95% of human antibiotic consumption.²³ In an AMS programme that prioritizes early review,
234 IV to oral switch, and short courses, we have shown that taking a pragmatic initial approach helps
235 our nursing colleagues, patients and the environment. Whilst it is clear that antibiotics are a precious
236 and limited resource, we believe it is important to consider the other resources that antibiotic

237 administration requires. Analysis of antibiotic use should be broadened to include a ‘triple bottom
238 line’ approach, considering impact on nursing workload, patient comfort, and environmental impact.
239 We believe that these are important considerations for institutional guidelines and should form part
240 of any contemporary AMS strategy. Integral to these concepts is actively monitoring the positive and
241 negative impact of changes and responding to the findings objectively.

242

243

244 **Competing interests**

245 The authors have no conflicts of interest to declare.

246 **Funding**

247 This work was supported by internal departmental funds.

248 **Acknowledgements**

249 The authors would like to thank Matthew Ordish for assistance in accessing Pyxis data and Peter
250 Wash for assistance in accessing hospital bed occupancy and demographic data.

251

252 References

- 253 1. Centers for Disease Control and Prevention. The Core Elements of Hospital Antibiotic
254 Stewardship Programs: 2019 [Internet]. Atlanta, GA: US Department of Health and Human
255 Services, CD. 2019 [cited 2023 Oct 25]. Available from: [https://www.cdc.gov/antibiotic-](https://www.cdc.gov/antibiotic-use/healthcare/pdfs/hospital-core-elements-H.pdf)
256 [use/healthcare/pdfs/hospital-core-elements-H.pdf](https://www.cdc.gov/antibiotic-use/healthcare/pdfs/hospital-core-elements-H.pdf)
- 257 2. Schuts EC, Hulscher MEJL, Mouton JW, Verduin CM, Stuart JWTC, Overdiek HWPM, et al.
258 Current evidence on hospital antimicrobial stewardship objectives: a systematic review and
259 meta-analysis. *Lancet Infect Dis*. 2016 Jul;16(7):847–56.
- 260 3. Bupha-Intr O. ‘empiric’ [Internet]. 2021 [cited 2023 Dec 9]. Available from:
261 <https://play.google.com/store/apps/details?id=online.aidanwilson.empiricupdate>
- 262 4. Jenkins A. IV to oral switch: a novel viewpoint. *Journal of Antimicrobial Chemotherapy*. 2023
263 Oct 3;78(10):2603–4.
- 264 5. Peters M. Time to solve persistent, pernicious and widespread nursing workforce shortages.
265 *Int Nurs Rev*. 2023 Jun 1;70(2):247–53.
- 266 6. Scheithauer S, Batzer B, Dangel M, Passweg J, Widmer A. Workload even affects hand
267 hygiene in a highly trained and well-staffed setting: a prospective 365/7/24 observational
268 study. *Journal of Hospital Infection*. 2017 Sep;97(1):11–6.
- 269 7. New Zealand Hospital Pharmacists’ Association. Notes on Injectable Drugs. 2021 Aug;
- 270 8. Rech MA, Gottlieb M. Intravenous Push Antibiotics Should be Administered in the Emergency
271 Department. *Ann Emerg Med*. 2021 Sep;78(3):384–5.
- 272 9. Academia EC, Jenrette JE, Mueller SW, McLaughlin JM. Evaluation of First-Dose, Intravenous
273 Push Penicillins and Carbapenems in the Emergency Department. *J Pharm Pract*. 2022 Jun
274 11;35(3):369–76.
- 275 10. Missiaen L, De Schoenmakere G, Valcke L, Decroix N. Assessment Intermittent Dosing of
276 Antibiotics: IV infusion or IV push? The impact of administration technique on dose delivered,
277 nursing practice and hospital budget. *Arch Med (Oviedo)*. 2022;14(1):1–3.
- 278 11. Tomson C. Reducing the carbon footprint of hospital-based care. *Future Hosp J*. 2015
279 Feb;2(1):57–62.
- 280 12. Smith M, Singh H, Sherman JD. Infection Prevention, Planetary Health, and Single-Use
281 Plastics. *JAMA*. 2023 Nov 28;330(20):1947.
- 282 13. Kadura S, Siala T, Arora VM. Perspective: leveraging the electronic health record to improve
283 sleep in the hospital. *Journal of Clinical Sleep Medicine*. 2023 Feb;19(2):421–3.
- 284 14. Arora VM, Machado N, Anderson SL, Desai N, Marsack W, Blossomgame S, et al. Effectiveness
285 of SIESTA on Objective and Subjective Metrics of Nighttime Hospital Sleep Disruptors. *J Hosp*
286 *Med*. 2019 Jan;14(1):38–41.
- 287 15. Zimmermann P, Curtis N. The effect of antibiotics on the composition of the intestinal
288 microbiota - a systematic review. *Journal of Infection*. 2019 Dec;79(6):471–89.

- 289 16. Meletiadiis J, Turlej-Rogacka A, Lerner A, Adler A, Tacconelli E, Mouton JW, et al. Amplification
290 of Antimicrobial Resistance in Gut Flora of Patients Treated with Ceftriaxone. *Antimicrob*
291 *Agents Chemother*. 2017 Nov;61(11).
- 292 17. Niehus R, van Kleef E, Mo Y, Turlej-Rogacka A, Lammens C, Carmeli Y, et al. Quantifying
293 antibiotic impact on within-patient dynamics of extended-spectrum beta-lactamase
294 resistance. *Elife*. 2020 May 7;9.
- 295 18. Munck C, Sheth RU, Cuaresma E, Weidler J, Stump SL, Zachariah P, et al. The effect of short-
296 course antibiotics on the resistance profile of colonizing gut bacteria in the ICU: a prospective
297 cohort study. *Crit Care*. 2020 Dec 9;24(1):404.
- 298 19. Saliba R, Mizrahi A, Gauthier P de P, Alban LM, Zahar JR, Pilmis B. Antimicrobial Stewardship
299 Program: Reducing Antibiotic’s Spectrum of Activity Is not the Solution to Limit the
300 Emergence of Multidrug-Resistant Bacteria. *Antibiotics*. 2022 Jan 7;11(1):70.
- 301 20. Miller AC, Arakkal AT, Sewell DK, Segre AM, Tholany J, Polgreen PM. Comparison of Different
302 Antibiotics and the Risk for Community-Associated *Clostridioides difficile* Infection: A Case-
303 Control Study. *Open Forum Infect Dis*. 2023 Aug 1;10(8).
- 304 21. Wilcox MH, Chalmers JD, Nord CE, Freeman J, Bouza E. Role of cephalosporins in the era of
305 *Clostridium difficile* infection. *Journal of Antimicrobial Chemotherapy*. 2017 Jan;72(1):1–18.
- 306 22. Slimings C, Riley T V. Antibiotics and hospital-acquired *Clostridium difficile* infection: update
307 of systematic review and meta-analysis. *Journal of Antimicrobial Chemotherapy*. 2014
308 Apr;69(4):881–91.
- 309 23. Duffy E, Ritchie S, Metcalfe S, Van Bakel B, Thomas MG. Antibacterials dispensed in the
310 community comprise 85%-95% of total human antibacterial consumption. *J Clin Pharm Ther*.
311 2018 Feb 1;43(1):59–64.

312

313

314

Table 1. Characteristics and outcomes of the cephalosporin cohort pre- and post-change in antimicrobial guidelines.

	Pre-change		Post-change		p-value
Total patients	8342		5107		
Received cefuroxime	7150	85.7%	296	5.8%	
Received ceftriaxone	1192	14.3%	4811	94.2%	
Age (years), median, IQR	60.3	(39.3,75.5)	64.9	(47.1,76.9)	<0.01
Female	4616	55.3%	2675	52.5%	<0.01
Ethnicity					0.01
Other or unknown	1486	17.8%	830	16.3%	
NZ Māori	1099	13.2%	679	13.3%	
Pacific Island	778	9.3%	569	11.1%	
NZ European	4335	52.0%	2643	51.8%	
Asian	644	7.7%	386	7.6%	
Specialty grouped					<0.01
General medicine	2273	27.2%	1700	33.3%	
Subspecialty medicine	429	5.1%	330	6.5%	
Hematology/Oncology	669	8.0%	471	9.2%	
Intensive care	181	2.2%	191	3.7%	
General surgery	2591	31.1%	1270	24.9%	
Subspecialty surgery	891	10.7%	596	11.7%	
Older persons' health	70	0.8%	42	0.8%	
Women's health	1023	12.3%	383	7.5%	
Emergency department ^a	202	2.4%	119	2.3%	
Other	13	0.2%	4	0.1%	
Hospitalized in the last 365 days	4139	49.6%	2588	50.7%	0.21
CDI in prior 365 days	39	0.5%	43	0.8%	<0.01
Cefuroxime/ceftriaxone DOT within 30 days	4.1	2.9	4.0	2.7	0.01
Incident CDI within 30 days	54.0	0.6%	52	1.0%	0.02
ESBL/3GCR-E culture within 30 days	289	3.5%	159	3.1%	0.31

IQR, inter quartile range; CDI, *Clostridioides difficile* infection; DOT, days of therapy; ESBL/3GCRE-E, extended-spectrum beta-lactamase or third generation cephalosporin-resistant Enterobacterales.

^aAlthough emergency department Pyxis data were unavailable, some patients were still coded as being under emergency once they had been admitted to a ward and received their first antibiotic dose.

Table 2. Characteristics and outcomes of the comparator cohort pre- and post-change in antimicrobial guidelines.

	Pre-change		Post-change		p-value
Total patients	16547		7237		
Age	62.2	(39.7,76.2)	65.2	(47.2,77.8)	<0.01
Female	9232	55.8%	3847	53.2%	<0.01
Ethnicity					<0.01
Other or unknown	2566	15.5%	1005	13.9%	
NZ Māori	2349	14.2%	1052	14.5%	
Pacific Island	1466	8.9%	682	9.4%	
NZ European	9197	55.6%	4110	56.8%	
Asian	969	5.9%	388	5.4%	
Specialty grouped					<0.01
General medicine	3391	20.5%	1551	21.4%	
Subspecialty medicine	1974	11.9%	749	10.3%	
Hematology/Oncology	625	3.8%	267	3.7%	
Intensive care	141	0.9%	85	1.2%	
General surgery	1086	6.6%	369	5.1%	
Subspecialty surgery	6583	39.8%	3368	46.5%	
Older persons' health	399	2.4%	191	2.6%	
Women's health	1942	11.7%	483	6.7%	
Emergency department	340	2.1%	141	1.9%	
Other	66	0.4%	30	0.4%	
Hospitalized in the last 365 days	7647	46.2%	3377	46.7%	0.53
CDI in prior 365 days	80	0.5%	49	0.7%	0.06
Total antibiotic LOT within 30 days	3.4	3.4	4.1	3.5	<0.01
Incident CDI within 30 days	34.0	0.2%	13.0	0.2%	0.68
ESBL/3GCR-E positive culture within 30 days	234	1.4%	121	1.7%	0.13

IQR, inter quartile range; CDI, *Clostridioides difficile* infection; LOT, length of therapy; ESBL/3GCRE-E, extended-spectrum beta-lactamase or third generation cephalosporin-resistant Enterobacterales.

316

317

Table 3. Multiple logistic regression model for odds of incident CDI in the cephalosporin cohort, by different patient characteristics

	aOR	95% CI	p-value
Age	1.02 ^a	(1.00, 1.03)	0.01
Female	1.68	(1.12, 2.50)	0.01
Ethnicity			
Other or unknown	1.00		
NZ Māori	1.40	(0.71, 2.76)	0.34
Pacific Island	0.32	(0.09, 1.09)	0.07
NZ European	1.04	(0.61, 1.77)	0.89
Asian	0.64	(0.21, 1.90)	0.42
Specialty grouped			
General medicine	1.00		
Subspecialty medicine	1.74	(0.76, 3.96)	0.19
Hematology/Oncology	2.19	(1.15, 4.16)	0.02
Intensive care	2.52	(0.94, 6.77)	0.07
General surgery	1.12	(0.62, 2.01)	0.72
Subspecialty surgery	2.40	(1.32, 4.37)	<0.01
Older persons' health	2.68	(0.77, 9.25)	0.12
Women's health	0.41	(0.09, 1.90)	0.26
Emergency department	- ^b		
Other	- ^b		
Hospitalized in the last 365 days	1.41	(0.92, 2.15)	0.12
CDI in prior 365 days	11.30	(5.25, 24.33)	<0.01
Cefuroxime/ceftriaxone DOT within 30 days	1.07 ^a	(1.02, 1.13)	0.01
Post-change period patient	1.44	(0.97, 2.12)	0.07

aOR, adjusted odds ratio; CDI, *Clostridioides difficile* infection; DOT, days of therapy

^aOdds ratio here represents increased odds per unit increase in the variable.

^bInsufficient outcomes in these groups to generate an odds ratio.

318

319

320

321

Table 4. Mean usage and resource consumption for cefuroxime and ceftriaxone per quarter pre- and post-change in guidelines

	Mean per quarter		Difference
	Pre	Post	
Occupied bed days	36535	39022	2487
Days of therapy			
Cefuroxime	2067	105	-1962
Ceftriaxone	528	2494	1966
Total	2595	2599	4
Dosing events and estimated resource usage			
Cefuroxime dosing events	4958	237	-4721
Nursing hours consumption ^a	1818	87	-1731
Waste generated ^b (kg)	970	46	-923
Overnight doses ^c	1691	82	-1609
Ceftriaxone dosing events	675	2935	2260
Nursing hours consumption ^a	248	1076	828
Waste generated ^b (kg)	161	701	540
Overnight doses ^c	86	507	421
Total dosing events	5633	3172	-2461
Nursing hours consumption ^a	2065	1163	-902
Waste generated ^b (kg)	1131	748	-383
Overnight doses ^c	1777	588	-1189

^aBased on an assumed 22 minute delivery time.

^bBased on assumed infusion delivery.

^cOvernight dose defined as between 10pm and 6am.

322

323

324

325 **Figure Legend**

326 **Figure 1.** Thirty-day incidence of *Clostridioides difficile* infection by quarter in the cephalosporin and

327 comparator cohorts, with linear trend line and 95% confidence interval.

328

Incidence per 100 courses

